Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FGFR4-CAR T Cells in Recurrent or Refractory Rhabdomyosarcoma
NCT06865664Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of FGFR4-CAR T cells in rhabdomyosarcoma (RMS) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Sep 2025; status: recruiting.
02
Drugs
FGFR4-CAR T cells
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT06865664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06865664.